Skip to content

Study · Randomized controlled trial · n = 62 · 1990

3 results

Desmopressin acetate in uncomplicated coronary artery bypass surgery: a prospective randomized clinical trial.

Hedderich GS, Petsikas DJ, Cooper BA, Leznoff M, Guerraty AJ, Poirier NL, Symes JF, Morin JE

Canadian journal of surgery. Journal canadien de chirurgie1 Feb 1990Cited by 22 (Europe PMC)

PMID2405964 (opens in a new tab)PepBankPUB-02405964
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In uncomplicated coronary bypass patients, total blood loss did not differ between desmopressin and placebo.

    In plain wordsIn uncomplicated coronary bypass patients, total blood loss did not differ between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeTotal blood loss
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Total blood loss
    1716 ml
    DDAVP, +/- 688
    Total blood loss
    1826 ml
    placebo, +/- 849

    Source sentences

    Summary
    There was no difference in total blood loss between the placebo (1826 +/- 849 ml) and DDAVP groups (1716 +/- 688 ml).
    1 context sentence
    Summary · context
    In a prospective randomized trial, the authors evaluated the ability of DDAVP to reduce perioperative bleeding during uncomplicated coronary bypass operations. Sixty-two patients who underwent coronary artery bypass grafting were randomized to receive intraoperatively either a placebo or DDAVP.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In uncomplicated coronary bypass patients, total red cell transfusions were similar with desmopressin and placebo.

    In plain wordsIn uncomplicated coronary bypass patients, total red cell transfusions were similar with desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeTotal red cell transfusions
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Red cell transfusions
    3.6 units of blood
    DDAVP, +/- 0.8
    Red cell transfusions
    3.4 units of blood
    placebo, +/- 1.3

    Source sentences

    Summary
    Total red cell transfusions were similar in placebo (3.4 +/- 1.3 units of blood) and DDAVP groups (3.6 +/- 0.8 units).
    1 context sentence
    Summary · context
    In a prospective randomized trial, the authors evaluated the ability of DDAVP to reduce perioperative bleeding during uncomplicated coronary bypass operations. Sixty-two patients who underwent coronary artery bypass grafting were randomized to receive intraoperatively either a placebo or DDAVP.
  3. 03HumanNon-randomized trialMechanism

    In coronary bypass patients, vWF increased significantly after desmopressin, while the placebo increase was not significant.

    In plain wordsIn coronary bypass patients, a blood-clotting protein increased significantly after desmopressin, while the placebo increase was not significant.

    Peptide
    Desmopressin
    Outcome
    IncreasePostoperative von Willebrand factor
    Study

    n = 62

    Comparator
    Preoperative value
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    von Willebrand factor
    2.75 U
    DDAVP group, postoperative, +/- 0.94
    von Willebrand factor
    1.8 U
    DDAVP group, preoperative, +/- 0.88
    von Willebrand factor
    2.77 U
    placebo group, postoperative, +/- 1.06
    von Willebrand factor
    2.17 U
    placebo group, preoperative, +/- 1.51
    p
    < 0.001
    DDAVP group increase

    Source sentences

    Summary
    Only the increase in the DDAVP groups was significant (p less than 0.001).
    2 context sentences
    Summary · context
    von Willebrand factor levels increased postoperatively in both placebo (2.77 +/- 1.06 versus 2.17 +/- 1.51 U) and DDAVP groups (2.75 +/- 0.94 versus 1.80 +/- 0.88 U).
    Summary · context
    In a prospective randomized trial, the authors evaluated the ability of DDAVP to reduce perioperative bleeding during uncomplicated coronary bypass operations. Sixty-two patients who underwent coronary artery bypass grafting were randomized to receive intraoperatively either a placebo or DDAVP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.